Contact UsInvestorsCareersMediaScienceContact Us

Pfizer and BioNTech Receive Prestigious Prix Galien Canada Innovative Product Award for COMIRNATY, Canada’s First Approved COVID-19 Vaccine


More than 66 million doses of the vaccine have been administered in Canada to date

KIRKLAND, QUEBEC and MAINZ, GERMANY - November 15, 2023 – Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that COMIRNATY, the Pfizer-BioNTech COVID-19 Vaccine, has been named the 2023 winner of the Prix Galien Canada Innovative Product Award. COMIRNATY is indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in individuals 6 months of age and older.

One of the most prestigious awards in the field of Canadian pharmaceutical research and innovation, Prix Galien Canada recognizes the efforts and achievements in this field. The annual award was presented at a gala ceremony in Montreal on November 15, 2023.

The Prix Galien Canada Innovative Product Award is presented every year to the company that has developed a drug product or vaccine launched on the Canadian market and judged by the jury to have made the most significant overall contribution to patient care in Canada in terms of efficacy, safety, benefits, and innovation.

“We are honoured that COMIRNATY has been awarded with the 2023 Prix Galien Canada – Innovative Product Award and even prouder of the impact that Pfizer and BioNTech have had on Canada’s response to the COVID-19 pandemic since the authorization of this product in December 2020,” said Najah Sampson, President, Pfizer Canada. “It was the first COVID-19 vaccine to be authorized in this country, and to date over 66 million doses have been administered in Canada. Pfizer has a long-standing legacy in vaccines that is driven by scientific research and development and is deep-rooted in our commitment to preventing infections.”     

The COVID-19 vaccines (COMIRNATY®) by Pfizer and BioNTech are based on BioNTech’s proprietary mRNA technology and were developed by both companies. BioNTech is the Marketing Authorization Holder for COMIRNATY and its adapted vaccines (COMIRNATY Original/Omicron BA.4/BA.5; COMIRNATY Omicron XBB.1.5) in the United States, the European Union, the United Kingdom, Canada and other countries, and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries.

About the Prix Galien Canada
The Prix Galien is the most prestigious award in the field of Canadian pharmaceutical research and innovation. Referred to as the Nobel Prize of pharmaceutical research, it recognizes the efforts and achievements of pharmaceutical research and development. The Jury of the Prix Galien Canada is composed of eminent specialists involved in the sphere of Canadian and pharmaceutical research and is a completely independent body. The Prix Galien Canada is administered by the Health Research Foundation (HRF) of Innovative Medicines Canada.

About Pfizer Canada
Pfizer Canada ULC is the Canadian operation of Pfizer Inc., one of the world's leading biopharmaceutical companies. Our diversified healthcare portfolio includes some of the world's best known and most prescribed medicines and vaccines. We apply science and our global resources to improve the health and well-being of Canadians at every stage of life. Our commitment is reflected in everything we do, from our disease awareness initiatives to our community partnerships. To learn more about Pfizer Canada, visit or you can follow us on LinkedInFacebookX or YouTube.

About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including DualityBio, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, OncoC4, Regeneron, Sanofi, and Pfizer.

For more information, please visit


Pfizer Canada Corporate Affairs
1-866-9-PFIZER (1 866 973-4937)
[email protected]

Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
[email protected]

About UsOur ProductsHelping Communities Our Voice Suppliers Distribution ChannelPfizer WorldwideMedia CentreTerms Of Use Careers Healthcare ProfessionalsContact UsPrivacy PolicyCopyright © Pfizer Canada 2022 All rights reserved. The information is intended only for residents of Canada. ® Pfizer Inc, used under license